MIAMI, June 11, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced the appointment of Dr. James Lee to its scientific advisory board (SAB) to help guide development of PAS-004 for the treatment of ETS2 pathway inflammatory diseases including inflammatory bowel disease (IBD), ulcerative colitis, Crohn’s disease, primary sclerosing cholangitis ...

-- Demonstrates PAS-004’s potential as a differentiated MEK inhibitor for immune-mediated inflammatory diseases such as IBD and ankylosing spondylitis – -- Positions PAS-004 for potential expansion beyond MAPK pathway driven tumors into inflammatory diseases – -- PAS-004 outperforms FDA-approved MEK inhibitor selumetinib in targeting ETS2 pathway – -- Study conducted at Francis Crick Institute by lead author of 2024 Nature paper that identified ETS2 as a central regulator of macrophage-driven Inflammation i ...

报告行业投资评级 未提及 报告的核心观点 - 五一假期临近，EUA延续弱势，短期震荡，震荡区间€60 - 68，中期偏强 [1] - 利多因素包括特朗普签署行政令缓解汽车关税影响、欧洲大陆风速下降抑制风电产出、普京坚持停战协议加入乌东四州条件 [1] - 利空因素为欧洲气温高于正常水平，太阳能发电量高，压制剩余负荷 [1] - 欧盟将于2027年实施ETS2（覆盖建筑与交通领域），首批EUA2期货合约将于2025年5月6日上线交易 [1] 根据相关目录分别进行总结 行情 - 一级拍卖价格63.55欧元/吨，较之前下降1.01%，投标覆盖比1.45 [1] - 二级EUA期货收盘价64.85欧元/吨，较之前下降0.70%，成交2.49万手，较之前增加0.14 [1] - 2025年4月29日EUA现货结算价63.82欧元/吨，较之前下降0.72%，现货成交量71手 [3] 拍卖信息 |日期|EUA拍卖量（万吨）|EUA拍卖价格（欧元/吨）|CBAM证书价格（欧元/吨）|投标覆盖比|拍卖收入（万欧元）| | ---- | ---- | ---- | ---- | ---- | ---- | |2025 - 04 - 29|20625|63.55|64.07|1.45|未提及| |2025 - 04 - 28|未提及|64.20|65.41|1.59|20836| [2]